Patients with aHUS are at ongoing risk of systemic, life-threatening, and sudden complications1-4

aHUS patients can show involvement in more than one organ system5-8,*

Click the round targets below, for the aHUS effects on the organ system.

*The organ-specific symptoms associated with aHUS are reported from published literature and are not limited to only those listed above. Other macrovascular complications include peripheral arterial disease and phalangeal gangrene12

In one study, 42% (8/19) of patients progressed to end-stage renal disease or death without overt signs and symptoms of TMA4

In aHUS, excessive complement activation leads to systematic TMA, progressive worsening of vital organ function, and multiorgan failure13-16

1. Legendre CM, et al. N Engl J Med. 2013;368(23):2169-2181. 2. Azoulay E, et al. Chest. 2017;152(2):424-434. 3. Goodship THJ, et al. Kidney Int. 2017;91(3):539-551. 4. Fremeaux-Bacchi V, et al. Clin J Am Soc Nephrol. 2013;8(4):554-562. 5. Campistol JM, et al. Nefrologia. 2015;35(5):421-447. 6. Jamme M, et al. PLoS One. 2017;12(5):e0177894. 7. Hofer J, et al. Front Pediatr. 2014;2:1-16. 8. Krishnappa V, et al. Ther Apher Dial. 2018;22(2):178-188. 9. Muus P, Loirat C, Licht C, et al. Presented at: 18th Congress of the European Hematology Association. June 13-16, 2013; Stockholm, Sweden. Abstract B1774. 10. Sallee M, et al. Nephrol Dial Transplant. 2010;25(6):2028-2032. 11. Sellier-Leclerc A-L, et al. J Am Soc Nephrol. 2007;18(8):2392-2400. 12. Noris M, et al. Nat Rev Nephrol. 2014;10(3):174-180. 13. Laurence J, et al. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2-15. 14. Noris M, et al. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. 15. Caprioli J, et al. Blood. 2006;108(4):1267-1279. 16. Langman C. Haematologica. 2012;97(s1):195-196.